Indications for symptomatic treatment of cognitive and psychopathological disorders in multiple sclerosis;Indications thérapeutiques à visée symptomatique des troubles cognitifs et psychopathologiques dans la sclérose en plaques

Revue Neurologique

Volumn 157, Issue 8-9 II, 2001, Pages 1085-1090

  Lebrun, C ^a  

^a PASTEUR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ATTENTION; COGNITIVE DEFECT; CONFERENCE PAPER; DEPRESSION; DISEASE COURSE; HUMAN; MEMORY; MENTAL DISEASE; MULTIPLE SCLEROSIS; PALLIATIVE THERAPY; TREATMENT INDICATION;

COGNITION DISORDERS; DEMENTIA; DEPRESSIVE DISORDER; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; PSYCHOTROPIC DRUGS;

EID: 0034799388     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Fatique in multiple sclerosis and its relationship to depression and neurologic disability
2. Brain MRI lesions and atrophy are related to depression in multiple sclerosis
3. Moclobemide treatment im multiple sclerosis patients with comorbod depression: An open-label safety trial
4. Lesion pattern in pateints with multiple sclerosis and depression
5. The brief repeatable battery of neuropsychological tests for multiple sclerosis
6. Treatment with oral 3,4 diaminopyridine improves leg strengh in multiple sclerosis
7. Emotional state of patients with relapsing-remitting MS treated with IFNβ1b
8. Long and short lasting side effects of high dose methylprednisolone pulse therapy in multiple sclerosis. A Study of 1527 courses
9. Cognitive function in primary progressive and transitionnal progressive multiple sclerosis. A controlled study with MRI correlates
10. The perceived effects of smoked cannabis on patients with multiple sclerosis
11. Neuropsychological impairments in chronic fatigue syndrom, multiple sclerosis, and depression
12. Neuropsychitric manifestations of multiple sclerosis
13. Does high-dose interferon β1b improve clinical response in more severly disabled multiple sclerosis patients?
14. Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis
15. Clinically isolated lesions of the type seen in multiple sclerosis followed up: A cognitive, psychiatric and MRI study
16. Multiple sclerosis disease modifying treatments and depression: A critical methodological review
17. Hospital-based psychiatric service utilization and morbidity in multiple sclerosis
18. Effect of fluoxetine on patients with multiple sclerosis
19. The effects of amantadine and pemoline on cognitive functionning in multiple sclerosis
20. A 12-week open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments
21. The social impact of multiple sclerosis-A study of 305 patients and their relatives
22. Serial neuropsychological assessement
23. Possible use of amantadine in depression
24. Interferon-β-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
25. Quality of life and its relationship to brain lesions and atrophy an MRI in 60 patients with MS
26. Changes in short-term memory processes in patients with multiple sclerosis
27. Fatigue in multiple sclerosis: Relationship to depression, disability, and disease pattern
28. Neurologic impairment in MS and disability status scale
29. Memory loss functioning and emotional changes in early phase multiple sclerosis
30. Management of patients receiving IFNβ1b for multiple sclerosis: Report of a consensus conference
31. Mood disorders in multiple sclerosis: Diagnosis and treatment
32. The effect of interferonβ1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis
33. Course of depression during the initiation of IFNβ1a treatment for multiple sclerosis
34. Side effect profile of interferonsβ-1b in multiple sclerosis: Result of an open label trial
35. A new appraoch to affective symptoms in relapsing-remitting multiple sclerosis
36. Pulsed methylprednisolone induces a reversible impairment of memory in patients with relapsing-remitting multiple sclerosis
37. Depression in multiple sclerosis
38. Étude du transfert interhémisphérique dans la SEP. Corrélations morpho-fonctionnelles
39. Troubles cognitifs et emotionnels dans la sclerose en plaques. Peut-on envisager une stratégie de prise en charge?
40. Neuropharmacology and therapeutic potential of cannabinoids
41. Patients with multiple sclerosis presenting to psychiatric hospitals
42. Improved visual reproduction test performance in multiple sclerosis patients receiving IFNβ1b
43. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns and predictions
44. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functionning
45. Depression and multiple sclerosis
46. Treatment of pathologic laughing and weeping with amitriptylline
47. Association between bipolar affective disorder and multiple sclerosis
48. Antidepressant pharmacotherapy of depression associated with multiple sclerosis
49. The spectrum of depression in multiple sclerosis
50. Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the caroll scale
51. Affective disorders in patients with multiple sclerosis: Pathophysiology and approaches to management
52. A longitudinal study of brain atrophy in relapsing multiple sclerosis
53. How often is multiple sclerosis mistaken for psychiatric disorder?
54. Suicide and multiple sclerosis: An epidemiological investigation
55. Paroxetine for depersonalization associated with multiple sclerosis
56. Depression as a major symptom of multiple sclerosis